Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating different magnesium supplementation protocols in critically ill patients, such as those with severe infections, heart attacks, or respiratory failure. This trial compares a higher magnesium target level to a lower target level to determine which leads to better survival and fewer cases of atrial fibrillation within 30 days. The study is a phase 4, randomized controlled trial embedded within electronic medical records across multiple hospitals. Participants will receive magnesium replacement according to one of two protocols based on their magnesium blood levels. The lower target group receives magnesium sulfate doses based on specific blood magnesium thresholds, while the higher target group may receive magnesium sulfate, magnesium oxide, or magnesium glucoheptonate depending on their levels. Magnesium levels are monitored regularly, and dosing is adjusted accordingly. The study uses an open-label design without blinding. Participants will not be required to perform specific tasks or surveys. Their clinical data, including magnesium levels, medication use, and heart rhythm, will be monitored through the electronic medical record for up to 30 days. The main outcome measured is a composite of hospital mortality and days free of atrial fibrillation during ICU stay at 30 days. Secondary measures include organ support days, length of ICU and hospital stay, and several other health indicators. The total study duration extends to 90 days for some outcomes.